Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关

doi:10.16352/j.issn.1001-6325.2022.09.1391

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (9): 1391-1399.doi: 10.16352/j.issn.1001-6325.2022.09.1391

Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关

王娟¹, 张晓燕², 朱爱华², 于宏波², 范新丹², 汤春辉^3*, 姚秀芳⁴

1. 南通大学附属妇幼保健院妇产科,江苏南通 226001;
2. 南通大学附属如东医院妇产科,江苏南通 226400;
4. 南通大学附属如东医院病理科,江苏南通 226400;
3. 南通大学附属医院妇产科,江苏南通 226001

收稿日期:2021-11-16 修回日期:2022-05-09 出版日期:2022-09-05 发布日期:2022-09-02
通讯作者: ntfywys@126.com
基金资助:
江苏省南通市卫生健康委员会资助项目(QA2019048)

High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients

WANG Juan¹, ZHANG Xiao-yan², ZHU Ai-hua², YU Hong-bo², FAN Xin-dan², TANG Chun-hui^3*, YAO Xiu-fang⁴

1. Department of Obstetrics and Gynecology, the Affiliated Maternal and child Health Hospital of Nantong University, Nantong 226001;
2. Department of Obstetrics and Gynecology, the Affiliated Rudong Hospital of Nantong University, Nantong 226400;
4. Department of Pathology, the Affiliated Rudong Hospital of Nantong University, Nantong 226400;
3. Department of Obstetrics and Gynecology, the Affiliated Hospital of Nantong University, Nantong 226001, China

Received:2021-11-16 Revised:2022-05-09 Online:2022-09-05 Published:2022-09-02

摘要/Abstract

摘要： 目的探究X射线修复交叉互补蛋白6(Ku70/XRCC6)在上皮性卵巢癌(EOC)组织中的表达及对卵巢癌细胞的增殖、凋亡及迁移的影响。方法 Western blot检测9例卵巢癌患者的不同级别的癌组织及3例健康人正常卵巢组织中的Ku70的表达;免疫组化检测119例卵巢癌组织中Ku70的表达;分析其表达与临床病理参数的关系;Kaplan-Meier生存曲线分析其与患者5年生存率之间的关系;集落形成实验及CCK-8法分析卵巢癌细胞系HO8910中Ku70的表达对卵巢癌细胞增殖的影响;流式细胞测量术分析 Ku70的表达对卵巢癌细胞凋亡的作用;划痕实验及Transwell小室法分析Ku70的表达对卵巢癌细胞迁移的影响。结果 Ku70在卵巢癌组织中的表达高于正常卵巢组织;Ku70的表达与临床病理特征之间密切相关(P＜0.05);Ku70表达高的卵巢癌患者较低表达患者生存率低(P＜0.05);抑制Ku70的表达能降低卵巢癌细胞的增殖及迁移,增加卵巢癌细胞的凋亡(P＜0.05)。结论 Ku70的异常表达与卵巢癌的发生密切相关,有可能成为卵巢癌治疗的潜在靶点。

关键词: Ku70/XRCC6, 上皮性卵巢癌, 增殖, 凋亡, 迁移

Abstract: Objective To investigate the expression of X-ray-repaired cross complementary protein 6 (Ku70/XRCC6) in epithelial ovarian cancer(EOC) and its effects on the proliferation, apoptosis and migration of ovarian cancer cells. Methods Western blot was used to detect the expression of Ku70 in 9 ovarian cancer tissues of different grades and 3 normal ovarian tissues. Immunohistochemistry was used to detect the expression of Ku70 in 119 ovarian cancer tissues, and the relationship between Ku70 expression and clinicopathological parameters was analyzed. Kaplan-meier survival curve was used to analyze the relationship between Ku70 expression and 5-year survival. Colony formation and CCK-8 assay were used to analyze the effect of Ku70 expression on proliferation of ovarian cancer cells, and flow cytometry was used to detect the effect of Ku70 expression on apoptosis of ovarian cancer cells. The effect of Ku70 expression on ovarian cancer cell migration was analyzed by scratch test and Transwell chamber method. Results The expression of Ku70 in ovarian cancer tissues was higher than that in normal ovarian tissues. The expression of Ku70 was closely correlated with pathological features (P＜0.05). The survival rate of ovarian cancer patients with high Ku70 expression was lower than that of patients with low Ku70 expression(P＜0.05). Inhibiting the expression of Ku70 decreased poliferation and migration, and increased apoptosis of ovarian cancer cells (P＜0.05). Conclusions The abnormal expression of Ku70 is closely related to the occurrence of ovarian cancer and so Ku70 is a potential therapeutic target for ovarian cancer treatment.

Key words: Ku70/XRCC6, epithelial ovarian cancer, proliferation, apoptosis, migration

中图分类号:

R737.31

王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.

WANG Juan, ZHANG Xiao-yan, ZHU Ai-hua, YU Hong-bo, FAN Xin-dan, TANG Chun-hui, YAO Xiu-fang. High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients[J]. Basic & Clinical Medicine, 2022, 42(9): 1391-1399.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.09.1391

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I9/1391

参考文献 12

[1]	Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393: 1240-1253.
[2]	李家丽,刘颖. 非同源末端连接研究进展及其在肿瘤发生和治疗中的意义[J]. 基础医学与临床, 2019, 39: 899-903.
[3]	Jiang H, Lin Y, Yang CQ, et al. Quantitative assessment of the association between XRCC6 C1310G polymorphism and cancer risk[J]. Tumour Biol, 2013, 34: 779-785.
[4]	Li JJ, Gu QH, Li M, et al. Role of Ku70 and Bax in epigallocatechin-3-gallate-induced apoptosis of A549 cells in vivo[J]. Oncol Lett, 2013, 5: 101-106.
[5]	张妍,鞠桂芝,张坪,等.Ku70在宫颈癌组织中的表达及意义[J]. 中国妇幼保健, 2009, 24:1700-1702.
[6]	Rajaei M, Saadat I, Omidvari S, et al. Association between polymorphisms at promoters of XRCC5 and XRCC6 genes and risk of breast cancer[J]. Med Oncol, 2014, 31: 1-4.
[7]	Liu ZH, Wang N, Wang FQ, et al. High expression of XRCC5 is associated with metastasis through Wnt signal-ing pathway and predicts poor prognosis in patients with hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2019, 23: 7835-7847.
[8]	Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer[J]. N Engl J Med, 2019, 381: 1929-1939.
[9]	Hnizda A, Tesina P, Nguyen TB, et al. SAP domain forms a flexible part of DNA aperture in Ku70/80[J]. FEBS J, 2021, 288: 4382-4393.
[10]	Geng F, Zhang Y, Lu Z, et al. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells[J]. DNA Cell Biol, 2020, 39: 144-151.
[11]	Ihnen M, zu Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer[J]. Mol Cancer Ther, 2013, 12: 1002-1015.
[12]	Pucci S, Mazzarelli P, Sesti F, et al. Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression[J]. Cell Cycle, 2009, 8: 473-481.

[1]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[2]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.
[3]	钟金鹏, 杨莉, 王辉波, 陈红健, 李金伟, 文明洪, 吕云波. HMGB1减弱丹参酮ⅡA对大鼠心肌缺血/再灌注损伤的缓解作用[J]. 基础医学与临床, 2022, 42(9): 1333-1338.
[4]	沈永华, 汪峻峰, 程泽星, 冯娟娟. 秦皮甲素抑制人鼻咽癌细胞系HNE-3增殖[J]. 基础医学与临床, 2022, 42(8): 1237-1242.
[5]	张敏, 邢丹丹, 康文越, 林慧. 七氟醚减轻蛛网膜下腔出血大鼠早期脑损伤[J]. 基础医学与临床, 2022, 42(8): 1206-1212.
[6]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[7]	薛晋芳, 宋海飞, 陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[8]	江宁, 郭钧, 刘铖, 周举. 莪术醇抑制人骨肉瘤细胞系的增殖和促凋亡[J]. 基础医学与临床, 2022, 42(8): 1200-1205.
[9]	刘磊, 李世宝, 张好良. 沉默lnc-SLC2A12-10:1抑制人胃癌细胞系AGS增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(7): 1071-1076.
[10]	钟鸣, 于修义, 郭伟溪, 方正. 麦冬皂苷B抑制人食管鳞状细胞癌细胞系EC9706增殖和迁移[J]. 基础医学与临床, 2022, 42(7): 1053-1059.
[11]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[12]	康有力, 赵丹, 杜文静, 李莉. SIRT5通过调控ALDH5A1的琥珀酰化促进人乳腺癌细胞的增殖[J]. 基础医学与临床, 2022, 42(7): 1099-1107.
[13]	白冰, 张海芳, 杨庆良, 秦悦, 周晨龙, 宋歌, 王颖. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42(6): 940-944.
[14]	沙务嘎, 李隽. 高通量筛选NMNAT1抑制剂及其肿瘤杀伤作用[J]. 基础医学与临床, 2022, 42(6): 933-939.
[15]	郭婧, 李亚洁, 牟寒霜. LncRNA FGD5-AS1靶向miR-106a-5p减轻ox-LDL诱导的HUVECs损伤[J]. 基础医学与临床, 2022, 42(5): 768-775.

Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关

High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 15

编辑推荐

Metrics

本文评价